Pooyeh Farahmand

Dr. Pooyeh Farahmand

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 August 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
SGStefano Grosso
Stefano Grosso
AMAlberto Marini
Alberto Marini
KGKatarina Gyuraszova
Katarina Gyuraszova
JVJohan Vande Voorde
Johan Vande Voorde
ASAristeidis Sfakianos
Aristeidis Sfakianos
AWAnne E Willis
Anne E Willis
Malignant mesothelioma (MpM) is an aggressive, invariably fatal tumour that is causally linked with asbestos exposure. The disease primarily results from loss of tumour suppressor gene function and there are no ‘druggable’ driver oncogenes associated with MpM. To identify opportunities for management of this disease we have carried out polysome profiling to define the MpM translatome. We show that in MpM there is a selective increase in the translation of mRNAs encoding proteins required for ribosome assembly and mitochondrial biogenesis. This results in an enhanced rate of mRNA translation, abnormal mitochondrial morphology and oxygen consumption, and a reprogramming of metabolic outputs. These alterations delimit the cellular capacity for protein biosynthesis, accelerate growth and drive disease progression. Importantly, we show that inhibition of mRNA translation, particularly through combined pharmacological targeting of mTORC1 and 2, reverses these changes and inhibits malignant cell growth in vitro and in ex-vivo tumour tissue from patients with end-stage disease. Critically, we show that these pharmacological interventions prolong survival in animal models of asbestos-induced mesothelioma, providing the basis for a targeted, viable therapeutic option for patients with this incurable disease.

21 September 2023 in Communications Biology
Verified
Journal Article
Open access
PDF file
PRPaulina Rzasa
Paulina Rzasa
SWSarah Whelan
Sarah Whelan
PFPooyeh Farahmand
Pooyeh Farahmand
HCHong Cai
Hong Cai
IGInna Guterman
Inna Guterman
ARAlessandro Rufini
Alessandro Rufini
BRAF mutations occur early in serrated colorectal cancers, but their long-term influence on tissue homeostasis is poorly characterized. We investigated the impact of short-term (3 days) and long-term (6 months) expression of BrafV600E in the intestinal tissue of an inducible mouse model. We show that BrafV600E perturbs the homeostasis of intestinal epithelial cells, with impaired differentiation of enterocytes emerging after prolonged expression of the oncogene. Moreover, BrafV600E leads to a persistent transcriptional reprogramming with enrichment of numerous gene signatures indicative of proliferation and tumorigenesis, and signatures suggestive of metabolic rewiring. We focused on the top-ranking cholesterol biosynthesis signature and confirmed its increased expression in human serrated lesions. Functionally, the cholesterol lowering drug atorvastatin prevents the establishment of intestinal crypt hyperplasia in BrafV600E-mutant mice. Overall, our work unveils the long-term impact of BrafV600E expression in intestinal tissue and suggests that colorectal cancers with mutations in BRAF might be prevented by statins.

28 May 2025 in Methods and Protocols
Verified
Journal Article
Open access
PDF file
Sophie Adriana Josepha Maria RoversSophie Adriana Josepha Maria Rovers
Sophie Adriana Josepha Maria Rovers
PFPooyeh Farahmand
Pooyeh Farahmand
DLDana Yinfay Liu
Dana Yinfay Liu
LBLouize Brants
Louize Brants
CHChristophe Hermans
Christophe Hermans
ESEvelien Smits
Evelien Smits
The development of standardised, reproducible preclinical models is essential for advancing pleural mesothelioma (PM) research. Here, we present a simple and reliable minimally invasive transthoracic intrapleural injection technique that could improve the efficiency of orthotopic PM model generation. By incorporating a simple needle sleeve to control the injection depth, this method eliminates the need for surgery or general anaesthesia, reducing technical complexity and animal stress while ensuring precise delivery into the pleural cavity. We demonstrate the effectiveness of this approach by achieving a 100% tumour engraftment rate following the injection of AE17 tumour cells. Additionally, this technique has been successfully used for asbestos fibre injection in mesothelioma models, highlighting its versatility. By providing a more accessible, standardised alternative to existing methods, this protocol improves the reliability of PM models and facilitates broader adoption by researchers, including those with limited experience in invasive procedures.